Natural product derived immune-regulatory agents

International Immunopharmacology

Volumn 37, Issue , 2016, Pages 5-15

  Talmadge, James E ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Autoimmune; Infectious; Inflammatory diseases; Neoplastic

Indexed keywords

BCG VACCINE; BIOLOGICAL RESPONSE MODIFIER; BISPHOSPHONIC ACID DERIVATIVE; IMMUNOLOGICAL ADJUVANT; IMMUNOMODULATING AGENT; LEVAMISOLE; MURAMYL DIPEPTIDE; NATURAL PRODUCT; OLIGONUCLEOTIDE; POLYUNSATURATED FATTY ACID; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR;

ARTICLE; AUTOIMMUNE DISEASE; DRUG APPROVAL; DRUG MECHANISM; DRUG SCREENING; DRUG SYNTHESIS; HUMAN; IMMUNOREGULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFECTION; INFLAMMATORY DISEASE; MALIGNANT NEOPLASTIC DISEASE; META ANALYSIS (TOPIC); NONHUMAN; OFF LABEL DRUG USE; OPTIMISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); VACCINATION; AUTOIMMUNE DISEASES; COMMUNICABLE DISEASES; NEOPLASMS; PROCEDURES; TRENDS;

AUTOIMMUNE DISEASES; BIOLOGICAL PRODUCTS; COMMUNICABLE DISEASES; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOTHERAPY; NEOPLASMS; OFF-LABEL USE;

EID: 84960837003     PISSN: 15675769     EISSN: 18781705     Source Type: Journal    
DOI: 10.1016/j.intimp.2016.02.025     Document Type: Article

References (144)

1. Couzin-Frankel J: Breakthrough of the year Cancer immunotherapy Science 2013 342 2013 1432 1433
2. Coley WB The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893 Clin. Orthop. Relat. Res. 1991 3 11
3. G. Walsh Biopharmaceutical benchmarks 2014 Nat. Biotechnol. 32 2014 992 1000
4. Technology, talent and capital: state bioscience initiatives 2008: Battelle Technol. Partnership Pract., 2008.
5. H. Schellekens, and E. Moors Clinical comparability and European biosimilar regulations Nat. Biotechnol. 28 2010 28 31
6. J.W. Li, and J.C. Vederas Drug discovery and natural products: end of an era or an endless frontier? Science 325 2009 161 165
7. L. Pan, H. Chai, and A.D. Kinghorn The continuing search for antitumor agents from higher plants Phytochem. Lett. 3 2010 1 8
8. A.L. Harvey Natural products in drug discovery Drug Discov. Today 13 2008 894 901
9. D.J. Newman, G.M. Cragg, and K.M. Snader Natural products as sources of new drugs over the period 1981-2002 J. Nat. Prod. 66 2003 1022 1037
10. L. Pan, H.B. Chai, and A.D. Kinghorn Discovery of new anticancer agents from higher plants Front. Biosci. 4 2012 142 156
11. K.U. Bindseil, J. Jakupovic, D. Wolf, J. Lavayre, J. Leboul, and D. van der Pyl Pure compound libraries; a new perspective for natural product based drug discovery Drug Discov. Today 6 2001 840 847
12. C.S. Chen, J.C. Doloff, and D.J. Waxman Intermittent metronomic drug schedule is essential for activating antitumor innate immunity and tumor xenograft regression Neoplasia 16 2014 84 96
13. Wood JN From plant extract to molecular panacea: a commentary on Stone (1763) 'An account of the success of the bark of the willow in the cure of the agues' Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 2015 370
14. E.O. Haaff, S.M. Dresner, T.L. Ratliff, and W.J. Catalona Two courses of intravesical Bacillus Calmette-Guerin for transitional cell carcinoma of the bladder J. Urol. 136 1986 820
15. C.M. Pinsky, F.J. Camacho, D. Kerr, N.L. Geller, F.A. Klein, H.A. Herr, W.F. Whitmore, and H.F. Oettgen Intravesical administration of Bacillus Calmette-Guerin in patients with recurrent superficial carcinoma of the urinary bladder: report of a prospective, randomized trial Cancer Treat. Rep. 69 1985 47
16. H.W. Herr, D.M. Schwalb, Z.F. Zhang, P.C. Sogani, W.R. Fair, W.F. Whitmore Jr., and H.F. Oettgen Intravesical bacillus Calmette-Guerin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 13 1995 1404 1408
17. R.L. De Jager, P. Guinan, D.L. Lamm, O. Khanna, S. Brosman, J. De Kernion, R. Williams, C. Richardson, and D.J. Reitsma Long-term complete remission in bladder carcinoma in situ with intravesical TICE bacillus Calmette Guerin. Overview analysis of six phase II clinical trials Urology 38 1991 507 513
18. H.W. Herr, D.D. Wartinger, W.R. Fair, and H.F. Oettgen Bacillus Calmette-Guerin therapy for superficial bladder cancer: 10-year followup J. Urol. 147 1992 1020 1023
19. B.E. Ayres, T.R. Griffiths, and R.A. Persad Is the role of intravesical bacillus Calmette-Guerin in non-muscle-invasive bladder cancer changing? BJU Int. 105 Suppl. 2 2010 8 13
20. J.F. Jimenez-Cruz, C.D. Vera-Donoso, O. Leiva, M. Pamplona, L.A. Rioja-Sanz, M. Martinez-Lasierra, N. Flores, and M. Unda Intravesical immunoprophylaxis in recurrent superficial bladder cancer (Stage T1): multicenter trial comparing bacille Calmette-Guerin and interferon-alpha Urology 50 1997 529 535
21. J.M. Lage, W.C. Bauer, D.R. Kelley, T.L. Ratliff, and W.J. Catalona Histological parameters and pitfalls in the interpretation of bladder biopsies in Bacillus Calmette-Guerin treatment of superficial bladder cancer J Urol. 135 1986 916
22. E.O. Haaff, W.J. Caralona, and T.L. Ratliff Detection of interleukin-2 in the urine of patients with superficial bladder tumors after treatment with intravesical BCG J. Urol. 136 1986 970
23. K. Taniguchi, S. Koga, M. Nishikido, S. Yamashita, T. Sakuragi, H. Kanetake, and Y. Saito Systemic immune response after intravesical instillation of Bacille Calmette-Guerin (BCG) for superficial bladder cancer Clin. Exp. Immunol. 115 1999 131 135
24. R. Kaempfer, L. Gerez, H. Farbstein, L. Madar, O. Hirschman, R. Nussinovich, and A. Shapiro Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression J. Clin. Oncol. 14 1996 1778 1786
25. W.K. Amery, and J.P. Bruynseels Levamisole, the story and the lessons Int. J. Immunopharmacol. 14 1992 481 486
26. W. Korytowski, M. Wrona, and A.W. Girotti Radiolabeled cholesterol as a reporter for assessing one-electron turnover of lipid hydroperoxides Anal. Biochem. 270 1999 123 132
27. J. Symoens, and M. Rosenthal Levamisole in the modulation of the immune response: the current experimental and clinical state J. Reticuloendothel. Soc. 21 1977 175 221
28. R.F. Holcombe, T. Milovanovic, R.M. Stewart, and T.M. Brodhag Investigating the role of immunomodulation for colon cancer prevention: results of an in vivo dose escalation trial of levamisole with immunologic endpoints Cancer Detect. Prev. 25 2001 183 191
29. G.D. Roodman Cell biology of the osteoclast Exp. Hematol. 27 1999 1229 1241
30. A.H. Paterson, T.J. Powles, J.A. Kanis, E. McCloskey, J. Hanson, and S. Ashley Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer J. Clin. Oncol. 11 1993 59 65
31. K. Shibuya, C.D. Mathers, C. Boschi-Pinto, A.D. Lopez, and C.J. Murray Global and regional estimates of cancer mortality and incidence by site: II. Results for the global burden of disease 2000 BMC Cancer 2 2002 37
32. M.C. Winter, I. Holen, and R.E. Coleman Exploring the anti-tumour activity of bisphosphonates in early breast cancer Cancer Treat. Rev. 34 2008 453 475
33. M. Trinkaus, W.S. Ooi, E. Amir, S. Popovic, M. Kalina, H. Kahn, G. Singh, M.C. Gainford, and M. Clemons Examination of the mechanisms of osteolysis in patients with metastatic breast cancer Oncol. Rep. 21 2009 1153 1159
34. D. Santini, B. Vincenzi, G. Avvisati, G. Dicuonzo, F. Battistoni, M. Gavasci, A. Salerno, V. Denaro, and G. Tonini Pamidronate induces modifications of circulating angiogenetic factors in cancer patients Clin. Cancer Res. 8 2002 1080 1084
35. C. Melani, S. Sangaletti, F. Barazzetta, Z. Werb, and M. Colombo Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma Cancer Res. 67 2007 11438 11446
36. A.M. Badger, A.G. King, J.E. Talmadge, D.A. Schwartz, D.H. Picker, C.K. Mirabelli, and N. Hanna Induction of non-specific suppressor cells in normal Lewis rats by a novel azaspirane SK&F 105685 J. Autoimmun. 3 1990 485 500
37. A.M. Badger, M.J. DiMartino, J.E. Talmadge, D.H. Picker, D.A. Schwartz, J.W. Dorman, C.K. Mirabelli, and N. Hanna Inhibition of animal models of autoimmune disease and the induction of non-specific suppressor cells by SK&F 105685 and related azaspiranes Int. J. Immunopharmacol. 11 1989 839 846
38. A.G. King, D. Olivera, J.E. Talmadge, and A.M. Badger Induction of non-specific suppressor cells and myeloregulatory effects of an immunomodulatory azaspirane, SK&F 105685 Int. J. Immunopharmacol. 13 1991 91 100
39. P. Serafini, I. Borrello, and V. Bronte Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression Semin. Cancer Biol. 16 2006 53 65
40. A.C. Ochoa, A.H. Zea, C. Hernandez, and P.C. Rodriguez Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma Clin. Cancer Res. 13 2007 721s 726s
41. J.E. Talmadge Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy Clin. Cancer Res. 13 2007 5243 5248
42. A.S. Pak, M.A. Wright, J.P. Matthews, S.L. Collins, G.J. Petruzzelli, and M.R. Young Mechanisms of immune suppression in patients with head and neck cancer: presence of CD34(+) cells which suppress immune functions within cancers that secrete granulocyte-macrophage colony-stimulating factor Clin. Cancer Res. 1 1995 95 103
43. A.H. Zea, P.C. Rodriguez, M.B. Atkins, C. Hernandez, S. Signoretti, J. Zabaleta, D. McDermott, D. Quiceno, A. Youmans, A. O'Neill, J. Mier, and A.C. Ochoa Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion Cancer Res. 65 2005 3044 3048
44. N. Mirza All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients Cancer Res. 66 2006 9299 9307
45. B. Almand, J. Clark, E. Nikitina, J. van Beynen, N. English, S. Knight, D. Carbone, and D. Gabrilovich Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer J. Immunol. 166 2001 678 689
46. H. Ko, Y. Kim, Y. Kim, W. Chang, S. Ko, S. Chang, S. Sakaguchi, and C. Kang A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model Cancer Res. 67 2007 7477 7486
47. M.R. Young, and M.A. Wright Myelopoiesis-associated immune suppressor cells in mice bearing metastatic Lewis lung carcinoma tumors: gamma-interferon plus tumor necrosis factor-alpha synergistically reduces immune suppressor and tumor growth-promoting activities of bone marrow cells and diminishes tumor recurrence and metastasis Cancer Res. 52 1992 6335 6340
48. L.P. Seung, R.R. Weichselbaum, A. Toledano, K. Schreiber, and H. Schreiber Radiation can inhibit tumor growth indirectly while depleting circulating leukocytes Radiat. Res. 146 1996 612 618
49. A.J. Chou, E.S. Kleinerman, M.D. Krailo, Z. Chen, D.L. Betcher, J.H. Healey, E.U. Conrad III, M.L. Nieder, M.A. Weiner, R.J. Wells, R.B. Womer, and P.A. Meyers Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group Cancer 115 2009 5339 5348
50. D.D. Wood, M.J. Staruch, P.L. Durette, W.V. Melvin, and B.K. Graham Role of interleukin-1 in the adjuvanticity of muramyl dipeptide in vivo J.J. Oppenheim, S. Cohen, Interleukins, Lymphokines and Cytokines 1983 Raven Press New York 691
51. P.A. Meyers Muramyl tripeptide (mifamurtide) for the treatment of osteosarcoma Expert. Rev. Anticancer. Ther. 9 2009 1035 1049
52. N. Inohara, Y. Ogura, A. Fontalba, O. Gutierrez, F. Pons, J. Crespo, K. Fukase, S. Inamura, S. Kusumoto, M. Hashimoto, S.J. Foster, A.P. Moran, J.L. Fernandez-Luna, and G. Nunez Host recognition of bacterial muramyl dipeptide mediated through NOD2. Implications for Crohn's disease J. Biol. Chem. 278 2003 5509 5512
53. P. Fedorocko, Z. Hoferova, M. Hofer, and P. Brezani Administration of liposomal muramyl tripeptide phosphatidylethanolamine (MTP-PE) and diclofenac in the combination attenuates their anti-tumor activities Neoplasma 50 2003 176 184
54. F. Ellouz, A. Adam, R. Ciorbaru, and E. Lederer Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives Biochem. Biophys. Res. Commun. 59 1974 1317 1325
55. Z. Jakopin Murabutide revisited: a review of its pleiotropic biological effects Curr. Med. Chem. 20 2013 2068 2079
56. J.J. Killion, C.D. Bucana, R. Radinsky, Z. Dong, T. O'Reilly, G. Bilbe, L. Tarcsay, and I.J. Fidler Maintenance of intestinal epithelium structural integrity and mucosal leukocytes during chemotherapy by oral administration of muramyl tripeptide phosphatidylethanolamine Cancer Biother. Radiopharm. 11 1996 363 371
57. G.H. Werner, and P. Jolles Immunostimulating agents: what next? A review of their present and potential medical applications Eur. J. Biochem. 242 1996 1 19
58. A.M. Rutenburg, J.A. Goldbarg, and E.P. Pineda Leucine aminopeptidase activity; observations in patients with cancer of the pancreas and other diseases N. Engl. J. Med. 259 1958 469 472
59. R.G. Willighagen, and H.T. Planteydt Aminopeptidase activity in cancer cells Nature 183 1959 263 264
60. H. Umezawa, T. Aoyagi, H. Suda, M. Hamada, and T. Takeuchi Bestatin, an inhibitor of aminopeptidase B, produced by actinomycetes J. Antibiot. 29 1976 97 99
61. T. Aoyagi, H. Suda, M. Nagai, K. Ogawa, and J. Suzuki Aminopeptidase activities on the surface of mammalian cells Biochim. Biophys. Acta 452 1976 131 143
62. P.S. Morahan, P.J. Edelson, and K. Gass Changes in macrophage ectoenzymes associated with anti-tumor activity J. Immunol. 125 1980 1312 1317
63. K. Ino, P.J. Bierman, M.L. Varney, D.G. Heimann, C.A. Kuszynski, S.A. Walker, and J.E. Talmadge Monocyte activation by an oral immunomodulator (bestatin) in lymphoma patients following autologous bone marrow transplantation Cancer Immunol. Immunother. 43 1996 206 212
64. A. Urabe, Y. Mutoh, H. Mizoguchi, F. Takaku, and N. Ogawa Ubenimex in the treatment of acute nonlymphocytic leukemia in adults Ann. Hematol. 67 1993 63 66
65. T. Yasumitsu, S. Ohshima, N. Nakano, Y. Kotake, and S. Tominaga Bestatin in resected lung cancer. A randomized clinical trial Acta Oncol. 29 1990 827
66. R. Mawad, P.S. Becker, P. Hendrie, B. Scott, B.L. Wood, C. Dean, V. Sandhu, H.J. Deeg, R. Walter, L. Wang, H. Myint, J.W. Singer, E. Estey, and J.M. Pagel Phase II study of tosedostat with cytarabine or decitabine in newly diagnosed older patients with acute myeloid leukaemia or high-risk MDS Br. J. Haematol. 172 2016 238 245
67. S.M. Hitzerd, S.E. Verbrugge, G. Ossenkoppele, G. Jansen, and G.J. Peters Positioning of aminopeptidase inhibitors in next generation cancer therapy Amino Acids 46 2014 793 808
68. N. Kadowaki, S. Ho, S. Antonenko, R.W. Malefyt, R.A. Kastelein, F. Bazan, and Y.J. Liu Subsets of human dendritic cell precursors express different toll-like receptors and respond to different microbial antigens J. Exp. Med. 194 2001 863 869
69. P. Ahmad-Nejad, H. Hacker, M. Rutz, S. Bauer, R.M. Vabulas, and H. Wagner Bacterial CpG-DNA and lipopolysaccharides activate toll-like receptors at distinct cellular compartments Eur. J. Immunol. 32 2002 1958 1968
70. H. Hemmi, O. Takeuchi, T. Kawai, T. Kaisho, S. Sato, H. Sanjo, M. Matsumoto, K. Hoshino, H. Wagner, K. Takeda, and S. Akira A toll-like receptor recognizes bacterial DNA Nature 408 2000 740 745
71. A.M. Krieg CpG motifs in bacterial DNA and their immune effects Annu. Rev. Immunol. 20 2002 709 760
72. A. Krug, S. Rothenfusser, V. Hornung, B. Jahrsdorfer, S. Blackwell, Z.K. Ballas, S. Endres, A.M. Krieg, and G. Hartmann Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells Eur. J. Immunol. 31 2001 2154 2163
73. A.M. Krieg, A.K. Yi, S. Matson, T.J. Waldschmidt, G.A. Bishop, R. Teasdale, G.A. Koretzky, and D.M. Klinman CpG motifs in bacterial DNA trigger direct B-cell activation Nature 374 1995 546 549
74. G. Hartmann, and A.M. Krieg Mechanism and function of a newly identified CpG DNA motif in human primary B cells J. Immunol. 164 2000 944 953
75. J.D. Marshall Identification of a novel CpG DNA class and motif that optimally stimulate B cell and plasmacytoid dendritic cell functions J. Leukoc. Biol. 73 2003 781 792
76. Z.K. Ballas, W.L. Rasmussen, and A.M. Krieg Induction of NK activity in murine and human cells by CpG motifs in oligodeoxynucleotides and bacterial DNA J. Immunol. 157 1996 1840 1845
77. M. Roman, E. Martin-Orozco, J.S. Goodman, M.D. Nguyen, Y. Sato, A. Ronaghy, R.S. Kornbluth, D.D. Richman, D.A. Carson, and E. Raz Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants Nat. Med. 3 1997 849 854
78. H. Shirota, K. Sano, T. Kikuchi, G. Tamura, and K. Shirato Regulation of murine airway eosinophilia and Th2 cells by antigen-conjugated CpG oligodeoxynucleotides as a novel antigen-specific immunomodulator J. Immunol. 164 2000 5575 5582
79. H.J. Cho, K. Takabayashi, P.M. Cheng, M.D. Nguyen, M. Corr, S. Tuck, and E. Raz Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism Nat. Biotechnol. 18 2000 509 514
80. R.S. Chu, O.S. Targoni, A.M. Krieg, P.V. Lehmann, and C.V. Harding CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity J. Exp. Med. 186 1997 1623 1631
81. H.L. Davis Use of CpG DNA for enhancing specific immune responses Curr. Top. Microbiol. Immunol. 247 2000 171 183
82. S. Zwaveling, S.C. Ferreira Mota, J. Nouta, M. Johnson, G.B. Lipford, R. Offringa, S.H. van der Burg, and C.J. Melief Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides J. Immunol. 169 2002 350 358
83. K. Heckelsmiller, S. Beck, K. Rall, B. Sipos, A. Schlamp, E. Tuma, S. Rothenfusser, S. Endres, and G. Hartmann Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy Eur. J. Immunol. 32 2002 3235 3245
84. A.D. Sandler, H. Chihara, G. Kobayashi, X. Zhu, M.A. Miller, D.L. Scott, and A.M. Krieg CpG oligonucleotides enhance the tumor antigen-specific immune response of a granulocyte macrophage colony-stimulating factor-based vaccine strategy in neuroblastoma Cancer Res. 63 2003 394 399
85. Z.K. Ballas, A.M. Krieg, T. Warren, W. Rasmussen, H.L. Davis, M. Waldschmidt, and G.J. Weiner Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs J. Immunol. 167 2001 4878 4886
86. J. Vollmer, and A.M. Krieg Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists Adv. Drug Deliv. Rev. 61 2009 195 204
87. A.M. Krieg Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides Curr. Oncol. Rep. 6 2004 88 95
88. M.A. Cheever Twelve immunotherapy drugs that could cure cancers Immunol. Rev. 222 2008 357 368
89. R. Ammi, J. De Waele, Y. Willemen, I. Van Brussel, D.M. Schrijvers, E. Lion, and E.L. Smits Poly(I:C) as cancer vaccine adjuvant: knocking on the door of medical breakthroughs Pharmacol. Ther. 146 2015 120 131
90. B.G. Molenkamp, B.J.R. Sluijter, P.A.M. van Leeuwen, S.J.A.M. Santegoets, and S. Meijer Wijnands PGJTB, Haanen JBAG, van den Eertwegh AJM, Scheper RJ, de Gruijl TD: local administration of PF-3512676 CpG-B instigates tumor-specific CD8 + T-Cell reactivity in melanoma patients Clin. Cancer Res. 14 2008 4532 4542
91. C. Manegold, D. Gravenor, D. Woytowitz, J. Mezger, V. Hirsh, G. Albert, M. Al-Adhami, D. Readett, A.M. Krieg, and C.G. Leichman Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 26 2008 3979 3986
92. A.M. Krieg Toll-like receptor 9 (TLR9) agonists in the treatment of cancer Oncogene 27 2008 161 167
93. C.L. Curtis, C.E. Hughes, C.R. Flannery, C.B. Little, and J.L. Harwood Caterson B: n-3 fatty acids specifically modulate catabolic factors involved in articular cartilage degradation J. Biol. Chem. 275 2000 721 724
94. R.J. Flower, and M. Perretti Controlling inflammation: a fat chance? J. Exp. Med. 201 2005 671 674
95. L.V. Norling, and C.N. Serhan Profiling in resolving inflammatory exudates identifies novel anti-inflammatory and pro-resolving mediators and signals for termination J. Intern. Med. 268 2010 15 24
96. D.W. Gilroy, T. Lawrence, M. Perretti, and A.G. Rossi Inflammatory resolution: new opportunities for drug discovery Nat. Rev. Drug Discov. 3 2004 401 416
97. S.F. Nabavi, S. Bilotto, G.L. Russo, I.E. Orhan, S. Habtemariam, M. Daglia, K.P. Devi, M.R. Loizzo, R. Tundis, and S.M. Nabavi Omega-3 polyunsaturated fatty acids and cancer: lessons learned from clinical trials Cancer Metastasis Rev. 34 2015 359 380
98. J.W. Berg Can nutrition explain the pattern of international epidemiology of hormone-dependent cancers? Cancer Res. 35 1975 3345 3350
99. S. Tominaga Cancer incidence in Japanese in japan, Hawaii, and western United States Natl. Cancer Inst. Monogr. 69 1985 83 92
100. S.L. Goodstine, T. Zheng, T.R. Holford, B.A. Ward, D. Carter, P.H. Owens, and S.T. Mayne Dietary (n-3)/(n-6) fatty acid ratio: possible relationship to premenopausal but not postmenopausal breast cancer risk in U.S. women J. Nutr. 133 2003 1409 1414
101. P.C. Calder N-3 polyunsaturated fatty acids and immune cell function Adv. Enzym. Regul. 37 1997 197 237
102. D.P. Rose Dietary fatty acids and cancer Am. J. Clin. Nutr. 66 1997 998S 1003S
103. H. Bartsch, J. Nair, and R.W. Owen Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers Carcinogenesis 20 1999 2209 2218
104. E.A. de Deckere Possible beneficial effect of fish and fish n-3 polyunsaturated fatty acids in breast and colorectal cancer Eur. J. Cancer Prev. 8 1999 213 221
105. H. Tapiero, G.N. Ba, P. Couvreur, and K.D. Tew Polyunsaturated fatty acids (PUFA) and eicosanoids in human health and pathologies Biomed. Pharmacother. 56 2002 215 222
106. P.C. Calder Dietary modification of inflammation with lipids Proc. Nutr. Soc. 61 2002 345 358
107. A.P. Simopoulos Omega-3 fatty acids in inflammation and autoimmune diseases J. Am. Coll. Nutr. 21 2002 495 505
108. A.P. Simopoulos The importance of the omega-6/omega-3 fatty acid ratio in cardiovascular disease and other chronic diseases Exp. Biol. Med. 233 2008 674 688
109. A.C. Thiebaut, V. Chajes, M. Gerber, M.C. Boutron-Ruault, V. Joulin, G. Lenoir, F. Berrino, E. Riboli, J. Benichou, and F. Clavel-Chapelon Dietary intakes of omega-6 and omega-3 polyunsaturated fatty acids and the risk of breast cancer Int. J. Cancer 124 2009 924 931
110. J. Kim, S.Y. Lim, A. Shin, M.K. Sung, J. Ro, H.S. Kang, K.S. Lee, S.W. Kim, and E.S. Lee Fatty fish and fish omega-3 fatty acid intakes decrease the breast cancer risk: a case-control study BMC Cancer 9 2009 216
111. N.K. Khankari, P.T. Bradshaw, S.E. Steck, K. He, A.F. Olshan, J. Shen, J. Ahn, Y. Chen, H. Ahsan, M.B. Terry, S.L. Teitelbaum, A.I. Neugut, R.M. Santella, and M.D. Gammon Dietary intake of fish, polyunsaturated fatty acids, and survival after breast cancer: a population-based follow-up study on Long Island, New York Cancer 2015
112. D.S. Im Functions of omega-3 fatty acids and FFA4 (GPR120) in macrophages Eur. J. Pharmacol. 2015
113. M. Bjursell, X. Xu, T. Admyre, G. Bottcher, S. Lundin, R. Nilsson, V.M. Stone, N.G. Morgan, Y.Y. Lam, L.H. Storlien, D. Linden, D.M. Smith, Y.M. Bohlooly, and J. Oscarsson The beneficial effects of n-3 polyunsaturated fatty acids on diet induced obesity and impaired glucose control do not require Gpr120 PLoS One 9 2014 e114942
114. H. Chung, Y.S. Lee, R. Mayoral, D.Y. Oh, J.T. Siu, N.J. Webster, D.D. Sears, J.M. Olefsky, and L.G. Ellies Omega-3 fatty acids reduce obesity-induced tumor progression independent of GPR120 in a mouse model of postmenopausal breast cancer Oncogene 34 2015 3504 3513
115. P.C. Calder Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance Biochim. Biophys. Acta 2015 1851 469 484
116. H.F. Turk, and R.S. Chapkin Membrane lipid raft organization is uniquely modified by n-3 polyunsaturated fatty acids Prostaglandins Leukot. Essent. Fat. Acids 88 2013 43 47
117. S. Xia, X.P. Li, L. Cheng, M.T. Han, M.M. Zhang, Q.X. Shao, H.X. Xu, and L. Qi Fish oil-rich diet promotes hematopoiesis and alters hematopoietic niche Endocrinology 156 2015 2821 2830
118. T. Schumann, T. Adhikary, A. Wortmann, F. Finkernagel, S. Lieber, E. Schnitzer, N. Legrand, Y. Schober, W.A. Nockher, P.M. Toth, W.E. Diederich, A. Nist, T. Stiewe, U. Wagner, S. Reinartz, S. Muller-Brusselbach, and R. Muller Deregulation of PPARbeta/delta target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment Oncotarget 6 2015 13416 13433
119. D. Yan, Q. Yang, M. Shi, L. Zhong, C. Wu, T. Meng, H. Yin, and J. Zhou Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway Eur. J. Immunol. 43 2013 2943 2955
120. N. Petrovsky, and J.C. Aguilar Vaccine adjuvants: current state and future trends Immunol. Cell Biol. 82 2004 488 496
121. G. Leroux-Roels Unmet needs in modern vaccinology: adjuvants to improve the immune response Vaccine 28 Suppl. 3 2010 C25 C36
122. A.T. Glenny, C.G. Pope, H. Waddington, and U. Wallace Immunological notes. XVII-XXIV J. Pathol. Bacteriol. 29 1926 31 40
123. J.L. Grun, and P.H. Maurer Different T helper cell subsets elicited in mice utilizing two different adjuvant vehicles: the role of endogenous interleukin 1 in proliferative responses Cell. Immunol. 121 1989 134 145
124. J. Doorbar Molecular biology of human papillomavirus infection and cervical cancer Clin. Sci. (Lond.) 110 2006 525 541
125. D.M. Parkin The global health burden of infection-associated cancers in the year 2002 Int. J. Cancer 118 2006 3030 3044
126. D.R. Lowy, and J.T. Schiller Prophylactic human papillomavirus vaccines J. Clin. Invest. 116 2006 1167 1173
127. E.E. Mast, H.S. Margolis, A.E. Fiore, E.W. Brink, S.T. Goldstein, S.A. Wang, L.A. Moyer, B.P. Bell, and M.J. Alter Advisory Committee on Immunization P: a comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents MMWR Recomm. Rep. 54 2005 1 31
128. P.W. Kantoff, C.S. Higano, E.J. Small, J.B. Whitmore, M.W. Frohlich, and P.F. Schellhammer Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer J. Natl. Cancer Inst. 104 2012 1107 1109 (author reply 9-12)
129. J. Wang, T.R. McGuire, H.C. Britton, J.K. Schwarz, F.R. Loberiza Jr., J.L. Meza, and J.E. Talmadge Lenalidomide and cyclophosphamide immunoregulation in patients with metastatic, castration-resistant prostate cancer Clin. Exp. Metastasis 32 2015 111 124
130. A. Barden, E. Mas, K.D. Croft, M. Phillips, and T.A. Mori Short-term n-3 fatty acid supplementation but not aspirin increases plasma proresolving mediators of inflammation J. Lipid Res. 55 2014 2401 2407
131. H.S. Weintraub Overview of prescription omega-3 fatty acid products for hypertriglyceridemia Postgrad. Med. 126 2014 7 18
132. P.C. Calder n-3 fatty acids, inflammation and immunity: new mechanisms to explain old actions Proc. Nutr. Soc. 72 2013 326 336
133. S. Gandini, M. Puntoni, B.M. Heckman-Stoddard, B.K. Dunn, L. Ford, A. DeCensi, and E. Szabo Metformin and cancer risk and mortality: a systematic review and meta-analysis taking into account biases and confounders Cancer Prev. Res. 7 2014 867 885
134. J. Greenwood, L. Steinman, and S.S. Zamvil Statin therapy and autoimmune disease: from protein prenylation to immunomodulation Nat. Rev. Immunol. 6 2006 358 370
135. P. Serafini, K. Meckel, M. Kelso, K. Noonan, J. Califano, W. Koch, L. Dolcetti, V. Bronte, and I. Borrello Phosphodiesterase-5 inhibition augments endogenous antitumor immunity by reducing myeloid-derived suppressor cell function J. Exp. Med. 203 2006 2691 2702
136. K.A. Noonan, N. Ghosh, L. Rudraraju, M. Bui, and I. Borrello Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma Cancer Immunol. Res. 2014
137. S. Kusmartsev, Z. Su, A. Heiser, J. Dannull, E. Eruslanov, H. Kubler, D. Yancey, P. Dahm, and J. Vieweg Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma Clin. Cancer Res. 14 2008 8270 8278
138. M.R. Young, and T.A. Day Immune regulatory activity of vitamin d3 in head and neck cancer Cancers 5 2013 1072 1085
139. T. Welte, S.S. Zhang, T. Wang, Z. Zhang, D.G. Hesslein, Z. Yin, A. Kano, Y. Iwamoto, E. Li, J.E. Craft, A.L. Bothwell, E. Fikrig, P.A. Koni, R.A. Flavell, and X.Y. Fu STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity Proc. Natl. Acad. Sci. U. S. A. 100 2003 1879 1884
140. T. Wang, G. Niu, M. Kortylewski, L. Burdelya, K. Shain, S. Zhang, R. Bhattacharya, D. Gabrilovich, R. Heller, D. Coppola, W. Dalton, R. Jove, D. Pardoll, and H. Yu Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells Nat. Med. 10 2004 48 54
141. Y. Nefedova, M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng, R. Salup, R. Jove, and D. Gabrilovich Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer J. Immunol. 172 2004 464 474
142. H. Hock, M.J. Hamblen, H.M. Rooke, D. Traver, R.T. Bronson, S. Cameron, and S.H. Orkin Intrinsic requirement for zinc finger transcription factor Gfi-1 in neutrophil differentiation Immunity 18 2003 109 120
143. E. Passegue, W. Jochum, M. Schorpp-Kistner, U. Mohle-Steinlein, and E.F. Wagner Chronic myeloid leukemia with increased granulocyte progenitors in mice lacking junB expression in the myeloid lineage Cell 104 2001 21 32
144. T. Ghansah, K.H. Paraiso, S. Highfill, C. Desponts, S. May, J.K. McIntosh, J.W. Wang, J. Ninos, J. Brayer, F. Cheng, E. Sotomayor, and W.G. Kerr Expansion of myeloid suppressor cells in SHIP-deficient mice represses allogeneic T cell responses J. Immunol. 173 2004 7324 7330